Back to results
US 10,813,984 B2Granted
Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
AssigneeRhode Island Hospital
InventorJack R. Wands
Life of this patent
Estimating the term…
Abstract
The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.
Claims16
A method for reducing growth of an aspartate-β-hydroxylase (ASPH)-expressing tumor in a subject, comprising
- selecting a suitable ASPH peptide for said subject by contacting a subject-derived peripheral blood mononuclear cell (PBMC) or T cell with a purified ASPH peptide, wherein said ASPH peptide is selected from the group consisting of SEQ ID NOs:
- 1-45, and wherein a selected peptide is characterized as eliciting an ASPH-specific HLA class I- or class II-restricted T cell response;
- and
- administering to the subject a therapeutically effective amount of a purified said selected peptide.
1 more element
A method for preventing development of an aspartate-β-hydroxylase (ASPH)-expressing tumor in a subject, comprising
- identifying a subject suffering from an ASPH-expressing tumor;
- selecting a suitable ASPH peptide for said subject by contacting a subject-derived peripheral blood mononuclear cell (PBMC) or T cell with a purified ASPH peptide, wherein said ASPH peptide is selected from the group consisting of SEQ ID NOs:
- 1-45, and wherein a selected peptide is characterized as eliciting an ASPH-specific HLA class I- or class II-restricted T cell response;
- and
- administering to said subject a therapeutically effective amount of a purified said selected peptide.
2 more elements
A method for reducing metastasis of an aspartate-β-hydroxylase (ASPH)-expressing tumor in a subject, comprising
- selecting a suitable ASPH peptide for said subject by contacting a subject-derived peripheral blood mononuclear cell (PBMC) or T cell with a purified ASPH peptide, wherein said ASPH peptide is selected from the group consisting of SEQ ID NOs:
- 1-45, and wherein a selected peptide is characterized as eliciting an ASPH-specific HLA class I- or class II-restricted T cell response;
- and
- administering to the subject a therapeutically effective amount of a purified said selected peptide.
1 more element
Dependencies are inferred from the claim text.